Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Cost of Revenue (2017 - 2024)

Historic Cost of Revenue for Lexaria Bioscience (LEXX) over the last 11 years, with Q4 2024 value amounting to $2720.0.

  • Lexaria Bioscience's Cost of Revenue fell 4359.19% to $2720.0 in Q4 2024 from the same period last year, while for Aug 2025 it was $2720.0, marking a year-over-year decrease of 4359.19%. This contributed to the annual value of $2720.0 for FY2025, which is 4359.19% down from last year.
  • Lexaria Bioscience's Cost of Revenue amounted to $2720.0 in Q4 2024, which was down 4359.19% from $4822.0 recorded in Q4 2023.
  • In the past 5 years, Lexaria Bioscience's Cost of Revenue ranged from a high of $64478.0 in Q4 2020 and a low of $2720.0 during Q4 2024
  • Its 5-year average for Cost of Revenue is $23829.7, with a median of $15795.0 in 2022.
  • Per our database at Business Quant, Lexaria Bioscience's Cost of Revenue surged by 206007.43% in 2020 and then crashed by 9136.14% in 2021.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Cost of Revenue stood at $64478.0 in 2020, then tumbled by 91.36% to $5570.0 in 2021, then surged by 183.57% to $15795.0 in 2022, then tumbled by 69.47% to $4822.0 in 2023, then crashed by 43.59% to $2720.0 in 2024.
  • Its Cost of Revenue was $2720.0 in Q4 2024, compared to $4822.0 in Q4 2023 and $12747.0 in Q2 2023.